Adenosine A2A receptor blockade prevents cisplatin-induced impairments in neurogenesis and cognitive function

18Citations
Citations of this article
22Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Chemotherapy-induced cognitive impairment (CICI) has emerged as a significant medical problem without therapeutic options. Using the platinum-based chemotherapy cisplatin to model CICI, we revealed robust elevations in the adenosine A2A receptor (A2AR) and its downstream effectors, cAMP and CREB, by cisplatin in the adult mouse hippocampus, a critical brain structure for learning and memory. Notably, A2AR inhibition by the Food and Drug Administration-approved A2AR antagonist KW-6002 prevented cisplatin-induced impairments in neural progenitor proliferation and dendrite morphogenesis of adult-born neurons, while improving memory and anxiety-like behavior, without affecting tumor growth or cisplatin's antitumor activity. Collectively, our study identifies A2AR signaling as a key pathway that can be therapeutically targeted to prevent cisplatin-induced cognitive impairments.

Cite

CITATION STYLE

APA

Oliveros, A., Yoo, K. H., Rashid, M. A., Corujo-Ramirez, A., Hur, B., Sung, J., … Jang, M. H. (2022). Adenosine A2A receptor blockade prevents cisplatin-induced impairments in neurogenesis and cognitive function. Proceedings of the National Academy of Sciences of the United States of America, 119(28). https://doi.org/10.1073/pnas.2206415119

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free